SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical
company focused on developing engineered autologous T-cell therapy
(eACT™) products for the treatment of cancer, today announced that the
Company has entered into an exclusive, worldwide license with the
National Institutes of Health (NIH) for intellectual property related to
multiple T-cell receptor (TCR) based product candidates for the
treatment of tumors expressing mutated KRAS antigens.
Kite expects the first of the licensed KRAS product candidates to enter
clinical study in 2016 as part of the Company's Cooperative Research and
Development Agreement (CRADA) with the National Cancer Institute (NCI)
under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the
Surgery Branch at the NCI.
KRAS is one of the most commonly mutated genes in all of human cancer
and is involved in a broad range of solid tumors, such as pancreatic,
colorectal, and lung cancer, for which there are significant unmet
"Neoantigens are uniquely present in tumors but absent in healthy tissue
which makes them attractive targets for using our TCR technology,"
stated Arie Belldegrun, M.D., FACS, Kite's Chairman, President and Chief
Executive Officer. "Kite has taken an important step toward building the
first therapeutic franchise of its kind for cancers driven by KRAS
mutations and has further expanded its efforts in building a TCR
portfolio across key classes of antigens, including cancer testis and
Pursuant to the terms of the license agreement, NIH will receive from
Kite an upfront payment and certain clinical, regulatory, and sales
milestone payments, as well as royalties on net sales of products
covered by the license.
About Kite Pharma
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system's ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Kite Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
advance and the success of TCR-based product candidates directed against
KRAS antigens and the ability, timing and willingness of the NCI to
continue research and development activities pursuant to the CRADA.
Various factors may cause differences between Kite's expectations and
actual results as discussed in greater detail in Kite's filings with the
Securities and Exchange Commission, including without limitation in its
Form 10-Q for the quarter ended June 30, 2016. Any forward-looking
statements that are made in this press release speak only as of the date
of this press release. Kite assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920006760/en/
Communications & Investor Relations
VP, Investor Relations
Source: Kite Pharma, Inc.
News Provided by Acquire Media